Ownership and insider activity for Pharvaris N.V. (PHVS): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases.
Price
| Price | $33.53 (closing price, October 30, 2026) |
| Market Cap | $2.3B |
| Exchange | NASDAQ |
| Country | CH |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-10-11 | Lu Peng | F-InKind | 109 | $3K |
| 2026-10-12 | Lu Peng | F-InKind | 117 | $4K |
| 2026-09-23 | Monges Viviane | M-Exempt | 11,969 | $96K |
| 2026-09-23 | Monges Viviane | M-Exempt | 11,969 | $96K |
| 2026-09-23 | Monges Viviane | S-Sale | 11,969 | $396K |
| 2026-09-22 | Lu Peng | M-Exempt | 45,308 | $117K |
| 2026-09-22 | Lu Peng | M-Exempt | 45,308 | $117K |
| 2026-09-22 | Schikan Johannes Gerardus Christiaan Petrus | M-Exempt | 800 | $16K |
| 2026-09-22 | Schikan Johannes Gerardus Christiaan Petrus | S-Sale | 800 | $29K |
| 2026-09-22 | Schikan Johannes Gerardus Christiaan Petrus | M-Exempt | 800 | $16K |
Balance Sheet (10y)
| Year | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | 4.8M EUR | 5.4M EUR | 20.3M EUR | 98.6M EUR | 209.4M EUR | 161.8M EUR | 391.2M EUR | 280.7M EUR | 291.7M EUR |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Receivables | 1,056 EUR | 0 | 210,843 EUR | 569,578 EUR | 700,079 EUR | 382,468 EUR | 1.0M EUR | 2.9M EUR | 4.6M EUR |
| Inventory | 0 | 0 | 0 | 0 | 0 | 4.0M EUR | 0 | 0 | 0 |
| Total Current Assets | 4.8M EUR | 5.4M EUR | 20.6M EUR | 101.0M EUR | 211.6M EUR | 166.8M EUR | 397.9M EUR | 289.4M EUR | 299.2M EUR |
| Property, Plant & Equipment | 0 | 0 | 12,927 EUR | 48,503 EUR | 351,349 EUR | 626,439 EUR | 455,571 EUR | 1.5M EUR | 1.4M EUR |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Assets | 4.8M EUR | 5.4M EUR | 20.6M EUR | 101.1M EUR | 212.1M EUR | 167.7M EUR | 398.7M EUR | 291.4M EUR | 301.5M EUR |
| Accounts Payable | 60,472 EUR | 246,356 EUR | 517,771 EUR | 656,448 EUR | 2.1M EUR | 6.0M EUR | 2.9M EUR | 4.6M EUR | 5.1M EUR |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Liabilities | 138,836 EUR | 481,340 EUR | 1.9M EUR | 5.3M EUR | 7.0M EUR | 18.2M EUR | 14.6M EUR | 23.0M EUR | 29.6M EUR |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 138,836 EUR | 481,340 EUR | 1.9M EUR | 5.3M EUR | 7.1M EUR | 18.5M EUR | 14.6M EUR | 23.6M EUR | 30.2M EUR |
| Retained Earnings | -6.1M EUR | -10.4M EUR | -18.5M EUR | -44.5M EUR | -87.6M EUR | -164.2M EUR | -265.9M EUR | -402.3M EUR | -579.6M EUR |
| Total Equity | 4.7M EUR | 5.0M EUR | 18.7M EUR | 95.8M EUR | 205.0M EUR | 149.3M EUR | 384.0M EUR | 267.8M EUR | 271.3M EUR |
| Total Debt | 0 | 0 | 0 | 0 | 250,184 EUR | 436,822 EUR | 238,905 EUR | 861,470 EUR | 776,798 EUR |
| Net Debt | -4.8M EUR | -5.4M EUR | -20.3M EUR | -98.6M EUR | -209.1M EUR | -161.4M EUR | -391.0M EUR | -279.9M EUR | -290.9M EUR |
| Working Capital | 4.7M EUR | 5.0M EUR | 18.7M EUR | 95.6M EUR | 204.6M EUR | 148.6M EUR | 383.2M EUR | 266.4M EUR | 269.6M EUR |
Financial Health
| Debt / Equity | 0.00 |
| Current Ratio | 11.94 |
| Piotroski F-Score | 1 |
| Altman Z-Score | 24.30 |
Profitability
| Return on Equity | -61.24% |
| Return on Invested Capital | -60.72% |
| Return on Assets | -52.20% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: BMRN · VERA · TVTX · BCRX
Explore sector: Healthcare · Biotechnology
More sections of PHVS: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method today · Companies that pass the Lynch method today · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks